A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
In brief
This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.
Key facts
- Study ID
- NCT05662397
- Run by
- HotSpot Therapeutics, Inc
- People needed
- 77
- Starts
- 2023-03-15
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2025-02-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Florida Cancer Specialists — Sarasota, Florida, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Montefiore Einstein Comprehensive Cancer Center — The Bronx, New York, United States
- Providence Cancer Institute of Oregon — Portland, Oregon, United States
- Abramson Cancer Center — Philadelphia, Pennsylvania, United States
- University of Pittsburgh (UPMC), Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- University of Ottawa — Ottawa, Ontario, Canada
- Princess Margaret Cancer Center — Toronto, Ontario, Canada
- NEXT Oncology Barcelona IOB Hospital Quirónsalud — Barcelona, Spain
- Clínica Universidad de Navarra — Madrid, Spain
- NEXT Oncology Hospital Universitario Quirónsalud Madrid — Madrid, Spain
- Clínica Universidad de Navarra (Pamplona) — Pamplona, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.